MOUNTAIN VIEW, Calif., Feb. 27 (UPI) -- U.S. firm MAP Pharmaceuticals said Tuesday it has positive result from its phase 2 study of its pediatric asthma drug candidate.
The company said the drug -- a nebulized formulation of budesonide -- met its primary efficacy endpoints, including asthma control as assessed by changes in morning asthma symptom scores, compared to placebo.
The multi-center study is being done to test the treatment at two doses in children as young as 12 months old.
The study revealed no serious adverse events and the treatment was well tolerated, MAP said.
"The results of this phase 2 study support our efforts to develop the lowest dose nebulized maintenance therapy for treatment of young children with asthma," said Timothy Nelson, chief executive officer of MAP Pharmaceuticals. "Our goal is to provide patients with a faster, more convenient therapy with improved compliance at a lower dose that retains the proven efficacy of budesonide. We aim to improve the lives of young children suffering from asthma."
